VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO Breast 2020 | Importance of biomarkers when evaluating heterogeneity in HER2+ metastatic BC

Maria Vittoria Dieci • 26 May 2020
ESMO Breast 2020
Breast Cancer Antibodies Checkpoint Inhibitors Trastuzumab emtansine

Maria Vittoria Dieci, MD, of the University of Padua, Padova, Italy, reviews how current biomarkers are used in the stratification of HER2+ metastatic breast cancer (BC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Maria Vittoria Dieci

5:54
ROXANE: impact of 21-gene assay on treatment for early breast cancer
Maria Vittoria Dieci • 22 May 2020
5:01
ShortHER study: validating the AJCC prognostic stage in HER2+ breast cancer
Maria Vittoria Dieci • 14 May 2020

Related Videos

8:01
Immune oncology in breast cancer: KEYNOTE-086, NCI 10013, & AIPAC
Sangeetha Reddy • 16 Dec 2020
2:36
Tailoring medicine in breast cancer
Erika Hamilton • 15 Dec 2020
2:09
MARIO-3: eganelisib in TNBC
Erika Hamilton • 15 Dec 2020
1:14
HER2CLIMB: outcomes by hormone receptor status
Erika Hamilton • 15 Dec 2020
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals